Tham khảo Altretamine

  1. ↑ “Hexalen (altretamine) Capsule. Human Prescription Drug Label”. dailymed.nlm.nih.gov. Eisai Inc. Truy cập ngày 24 tháng 8 năm 2016.
  2. ↑ Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A (2003). “Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study”. Gynecol. Oncol. 88 (2): 118–22. doi:10.1016/S0090-8258(02)00103-8. PMID 12586589.
  3. ↑ Chan JK, Loizzi V, Manetta A, Berman ML (2004). “Oral altretamine used as salvage therapy in recurrent ovarian cancer”. Gynecol. Oncol. 92 (1): 368–71. doi:10.1016/j.ygyno.2003.09.017. PMID 14751188.
  4. ↑ Malik IA (2001). “Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer”. Jpn. J. Clin. Oncol. 31 (2): 69–73. doi:10.1093/jjco/hye012. PMID 11302345.
  5. ↑ Damia G, D'Incalci M (1995). “Clinical pharmacokinetics of altretamine”. Clinical Pharmacokinetics. 28 (6): 439–48. doi:10.2165/00003088-199528060-00002. PMID 7656502.
  6. ↑ Lemke, Thomas L.; Williams, David A. biên tập (2008). Foye's Principles of Medicinal Chemistry (ấn bản 6). Philadelphia: Lippincott Williams & Wilkins. ISBN 978-0-7817-6879-5.
  7. 1 2 Drugs.com: Altretamine Monograph
  8. ↑ Wiernik, P. H.; Yeap, B.; Vogl, S. E.; Kaplan, B. H.; Comis, R. L.; Falkson, G.; Davis, T. E.; Fazzini, E.; Cheuvart, B. (1992). “Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group”. Cancer investigation. 10 (1): 1–9. doi:10.3109/07357909209032783. PMID 1735009.

Liên quan